These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10147118)

  • 21. [A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Badía X; Segú L; García Alonso F; Rovira J
    Med Clin (Barc); 1993 Jan; 100(3):84-9. PubMed ID: 8426499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal therapy for bacteremia and sepsis.
    Guglielmo J; Wiener-Kronish JP
    West J Med; 1992 Aug; 157(2):174. PubMed ID: 1441476
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
    Quintiliani R; Cooper B; Maderazo E; Nightingale C
    Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibody to endotoxin in the treatment of gram-negative sepsis.
    Schentag JJ
    JAMA; 1992 May; 267(17):2326-7. PubMed ID: 1564766
    [No Abstract]   [Full Text] [Related]  

  • 26. Monoclonal antibodies in sepsis.
    Sheppard MJ; Kelly TW
    BMJ; 1992 Apr; 304(6833):1054-5. PubMed ID: 1586799
    [No Abstract]   [Full Text] [Related]  

  • 27. Monoclonal antibody HA-1A for gram-negative shock.
    Lancet; 1991 Apr; 337(8748):1036-7. PubMed ID: 1673184
    [No Abstract]   [Full Text] [Related]  

  • 28. [Fulminant meningococcemia treated with antiendotoxin IgM monoclonal antibodies (HA-1A)].
    Gómez-Jiménez J; Peracaula Picart R; Jódar Masanes R; Montoro Ronsano B
    Med Clin (Barc); 1993 Mar; 100(10):394-5. PubMed ID: 8474285
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia.
    Micek ST; Welch EC; Khan J; Pervez M; Doherty JA; Reichley RM; Hoppe-Bauer J; Dunne WM; Kollef MH
    J Hosp Med; 2011 Sep; 6(7):405-10. PubMed ID: 21916003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
    Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
    JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy of endotoxemia and septicemia.
    Baumgartner JD; Glauser MP
    Immunobiology; 1993 Apr; 187(3-5):464-77. PubMed ID: 8330909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
    Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
    Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment with monoclonal anti-endotoxin antibodies of patients with sepsis caused by Gram-negative bacteria].
    Ned Tijdschr Geneeskd; 1991 Jul; 135(28):1289-91. PubMed ID: 1861770
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-lipopolysaccharide antibodies in gram-negative bacteremia.
    Baumgartner JD
    Behring Inst Mitt; 1991 Feb; (88):216-21. PubMed ID: 2049041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
    Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.